For the second year straight, Redeye hosts a seminar on ‘Drug development in orphan indications.’

Targeting rare diseases come with several advantages in the regulatory, clinical development, and commercial stage. We find some of the biotech success stories on the stock market in this space. A couple of the companies stand on the verge of commercialization.

This is a unique opportunity for investors interested in this space. The participating companies will share their equity story, project status, and triggers ahead.

 

Schedule:

08.40 Theme Introduction – Anders Hedlund, Analyst Redeye
08.55 Respiratorius – Johan Drott, CEO
09.15 Xspray Pharma – Per Andersson, CEO
09.35 Vicore Pharma – Carl-Johan Dalsgaard, CEO
09.55 Egetis Therapeutics – Nicklas Westerholm, CEO & Peder Walberg, Operative Director of the Board
10.15 Orphazyme – Anders Fink Vadsholt, CFO & Christophe Bourdon, CEO
10.35 IBT Therapeutics – Staffan Strömberg, CEO
10.55 Abliva – Ellen Donnelly, CEO
11.15 Hansa BioPharma – Klaus Sindahl, IR-chef
11.35 Ascelia Pharma – Carl Bjartmar, CMO
11.55 Calliditas – Dr Richard Philipson, CMO
12.15 Saniona – Rami Levin, CEO
12.35 The End

 

Sign up for this event

 

This event is presented in English